Bristol-Myers Squibb Company (BMY)
BMY Price and Sentiment
BMY Latest news
Compugen's stock jumps after Bristol Myers Squibb completes $20 million investment into the company
2021-11-11 08:22Shares of Compugen Ltd. CGEN, -2.33% gained 13.4% in premarket trading on Thursday after Bristol Myers Squibb Co. BMY, -0.12% completed a $20 million investment in the company.
Bristol Myers Squibb to Take Part in Wolfe Research Virtual Healthcare Conference
2021-11-10 06:59NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Take Part in Wolfe Research Virtual Healthcare Conference
3 Rock-Solid Healthcare Dividend Stocks Now on Sale
2021-11-10 06:57Now may be a good time to buy these healthcare dividend giants.
The Best 9%-25%+ Undervalued Companies Today
2021-11-09 12:34Looking at the market today, it's clear that while some segments and companies suffer from overvaluation, this is far from a universal state. There are massively undervalued investment opportunities, where you essentially get paid to wait for the company to appreciate.
11 Exceptional November Dividend Buys
2021-11-09 10:43May-August 2021, Kiplinger Today listed eight sets of stocks sorted as: best-buys for 2021, infrastructure-plays, value, growth, small-cap, high-yield, housing-bets, and cash-flow-gushers. Those eight "exceptional-dividend" articles revealed 86 equities, 76 paying dividends. Kiplinger article titles were, '21 Best Stocks to Buy'; '14 Best Infrastructure Stocks'; '16 Best Value'; '10 Dividends-Growth'; '6 Small-Cap'; '10 High-Yield 4% or More'; '12 Housing'; '10 Cash-Flow-Gushers.'
3 Best Biotech Stocks to Buy in November
2021-11-08 07:15These companies could both diversify your portfolio and boost your dividend income.
Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
2021-11-08 06:59PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
2021-11-08 06:59PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Neoadjuvant Opdivo Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable NSCLC in Phase 3 CheckMate -816 Trial
4 No-Brainer Buffett Stocks to Buy With $500 in November
2021-11-08 05:51Riding the Oracle of Omaha's coattails has been a moneymaking move for decades.
FATE's Q3 Loss Narrower Than Expected, Pipeline in Focus
2021-11-05 10:42FATE reports a year-over-year wider loss on increased R&D expenses in the third quarter.